February 11, 2020 -
Portable MolecuLight i:X allows for imaging of harmful bacteria invisible to human eye
University Hospitals Ahuja Medical Center (UH) is the first clinical setting in Ohio using special technology to identify harmful bacteria, leading to healing for patients suffering from chronic wounds.
Windy Cole, DPM, Medical Director of the UH
… Read More
December 5, 2019 -New FDA Approval Extends Label to Including the i:X’s® Detection of Bacteria and Digital Wound Measurement
TORONTO, Canada – (December 5, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of fluorescence in wounds, has received FDA 510(k) clearance for its i:X® handheld fluorescence imaging device
… Read More
November 4, 2019 -Forthcoming Category lll CPT Code Reflects the Published Clinical Evidence and a Determination of Significant Value of Real-Time Fluorescence Imaging Across the Wound Care Treatment Pathway
TORONTO, Canada – (November 4, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of bacteria for chronic wounds, has
… Read More
October 11, 2019 -
Multiple Trials Illustrate the Significant Clinical Benefit of MolecuLight’s Point-of-Care Fluorescence Imaging Device for Chronic Wound Management
LAS VEGAS, USA and TORONTO, Canada – (October 11, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of bacteria for chronic wounds and its i:X point-of-care fluorescence imaging
… Read More
October 4, 2019 -
Point-of-Care Fluorescence Imaging for Chronic Wounds and its Significant Clinical Benefits are Featured at the Largest Canadian Wound Care Conference in 5 Clinical Talks and Posters
NIAGARA FALLS, Canada and TORONTO, Canada – (October 4, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization
… Read More
September 13, 2019 -Study Highlights the Utility of Bacterial Fluorescence Imaging to Provide Real-Time Information to Clinicians on a Wound’s Bacterial Burden that Significantly Impacted Treatment Decisions Read More
August 19, 2019 -
TORONTO, Canada – (August 20, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of bacteria for chronic wounds, announced it has secured a $7.5 million USD term loan from Oxford Finance LLC, a specialty finance firm providing senior debt to life sciences and healthcare services
… Read More
August 14, 2019 -
photonamic GmbH & Co. KG (Head office: Pinneberg, Germany; CEO: Ulrich Kosciessa, Ph.D.) (“photonamic”), a subsidiary of SBI Holdings, Inc. (Head office: Minato-ku,Tokyo; Representative Director, President and CEO: Yoshitaka Kitao) is engaged in the business of pharmaceutical development of 5-aminolevulinic acid (“5-ALA”) (*) hereby announces the acquisition of the
… Read More
August 14, 2018 -MolecuLight Inc. achieved a major regulatory milestone permitting expansion into the United States market. FDA has granted De Novo clearance for the ground-breaking wound fluorescence imaging device, the MolecuLight i:X. Read More